Journal of Hepatology
Volume 49, Issue 4 , Pages 625-633 , October 2008

Acute hepatitis C: Current status and remaining challenges

  • Teresa Santantonio

      Affiliations

    • Clinic of Infectious Diseases, University of Bari, Policlinico, Piazza G. Cesare 11, 70124 Bari, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +390805478237; fax: +390805478333.
    • Address: Internal Medicine, Immunology and Infectious Diseases, Piazza G. Cesare 11, Bari 70124, Italy.
    • ,
  • Johannes Wiegand

      Affiliations

    • Department of Internal Medicine II, University of Leipzig, Philipp-Rosenthal-Strasse 27, 04103 Leipzig, Germany
    • Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    • ,
  • J. Tilman Gerlach

      Affiliations

    • Department of Gastroenterology and Hepatology, University of Zurich, Rämistrasse 100, 8091 Zurich, Switzerland
    • Department of Gastroenterology and Hepatology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007 St. Gallen, Switzerland

References 

  1. Orland JR, Wright TL, Cooper S. Acute hepatitis C. Hepatology. 2001;33:321–327
  2. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008;47:321–331
  3. Mele A, Tosti ME, Marzolini A, Moiraghi A, Ragni P, Gallo G, et al. Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. SEIEVA collaborating Group. J Viral Hepat. 2000;7:30–35
  4. Tosti ME, Solinas S, Prati D, Salvaneschi L, Manca M, Francesconi M, et al. An estimate of the current risk of transmitting blood-borne infections through blood transfusion in Italy. Br J Haematol. 2002;117:215–219
  5. Kondili LA, Chionne P, Costantino A, Villano U, Lo Noce C, Pannozzo F, et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut. 2002;50:693–696
  6. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562
  7. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47:1–39
  8. Williams I. Epidemiology of hepatitis C in the United States. Am J Med. 1999;107:2S–9S
  9. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis United States, 2005. 56th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2007. p. 1–24.
  10. Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, et al. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154–1159
  11. Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, et al. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006;4:1278–1282
  12. Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148–162
  13. Martinez-Bauer E, Forns X, Armelles M, Planas R, Sola R, Vergara M, et al. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol. 2008;48:20–27
  14. Kubitschke A, Bader C, Tillmann HL, Manns MP, Kuhn S, Wedemeyer H. Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?. Der Internist (Berl). 2007;48:1165–1172
  15. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43:250–256
  16. Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130:632–638
  17. Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, et al. Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology. 2006;43:923–931
  18. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147–1171
  19. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264
  20. World Health Organization. Hepatitis C. World Health Organization 2000 October [cited 2006 Apr 12];1-3.
  21. Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003;35:104–113
  22. Heathcote J, Elewaut A, Fedail S, Gangl A, Hamid S, Shah M, et al. WGO practice guideline: management of acute viral hepatitis. World Gastroenterology Organisation Web site 2003 December [cited 2007 Sep 14]. Available from: URL: http://www.worldgastroenterology.org/management-of-acute-viral-hepatitis.html.
  23. Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol. 2005;42:S108–S114
  24. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36:S65–S73
  25. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis. 2005;25:7–17
  26. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41
  27. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung M-C, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–88
  28. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–64
  29. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–391
  30. Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, et al. Pegylated interferon α therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004;39:1721–1731
  31. Diepolder HM, Zachoval R, Hoffmann RM, Wierenga EA, Santantonio T, Jung MC, et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet. 1995;346:1006–1007
  32. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933–941
  33. Gruner NH, Gerlach TJ, Jung MC, Diepolder HM, Schirren CA, Schraut WW, et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis. 2000;181:1528–1536
  34. Lechner F, Gruener NH, Urbani S, Uggeri J, Santantonio T, Kammer AR, et al. CD8+ T lymphocyte responses are induced during acute hepatitis C virus infection but are not sustained. Eur J Immunol. 2000;30:2479–2487
  35. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395–1406
  36. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003;302:659–662
  37. Kamal SM, Amin A, Madwar M, Graham CS, He Q, Al Tawil A, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78:12252–12258
  38. Lucas M, Ulsenheimer A, Pfafferot K, Heeg MH, Gaudieri S, Gruner N, et al. Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS ONE. 2007;2:e649
  39. Amin J, Law MG, Micallef J, Jauncey M, Van BI, Kaldor JM, et al. Potential biases in estimates of hepatitis C RNA clearance in newly acquired hepatitis C infection among a cohort of injecting drug users. Epidemiol Infect. 2007;135:144–150
  40. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al. Interferon for acute hepatitis C (review). The Cochrane Library. 2002;(3):CD000369
  41. Cammà C, Almasio P, Craxı` A. Interferon as treatment for acute hepatitis C: a meta-analysis. Dig Dis Sci. 1996;41:1248–1255
  42. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24:778–789
  43. Licata A, Di Bona D, Schepis F, Shahied L, Craxı` A, Cammà C. When and how to treat acute hepatitis C?. J Hepatol. 2003;39:1056–1062
  44. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452–1457
  45. Wiegand J, Jackel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004;40:98–107
  46. Delwaide J, Bourgeois N, Gerard C, De Maeght S, Mokaddem F, Wain E, et al. Treatment of acute hepatitis C with interferon α-2b: early initiation of treatment is the most effective predictive factor of sustained viral response. Aliment Pharmacol Ther. 2004;20:15–22
  47. Vogel W, Graziadei I, Umlauft F, Datz C, Hackl F, Allinger S, et al. High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C: a pilot study. Dig Dis Sci. 1996;41:81S–85S
  48. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004;39:1213–1219
  49. Santantonio T, Fasano M, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, et al. Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–333
  50. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Raiteri R, et al. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C. J Antimicrob Chemother. 2006;57:360–363
  51. De Rosa FG, Bargiacchi O, Audagnotto S, Garazzino S, Cariti G, Calleri G, et al. Twelve-week treatment of acute hepatitis C virus with pegylated interferon-α-2b in injection drug users. Clin Infect Dis. 2007;45:583–588
  52. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-α in acute HCV hepatitis. J Viral Hepat. 2007;14:116–121
  53. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–450
  54. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–2848
  55. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–459
  56. Dominguez S, Ghosn J, Valantin M-A, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS. 2006;20:1157–1161
  57. Gilleece YC, Browne RE, Asboe D, Atkins M, Mandalia S, Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr. 2005;40:41–46
  58. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS. 2006;20:233–240
  59. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, et al. Pegylated interferon-α for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antiviral Therapy. 2006;11:1097–1101
  60. Poordad FF, Fabrizi F, Martin P. Hepatitis C infection associated with renal disease and chronic renal failure. Semin Liver Dis. 2004;24:69–77
  61. Rocha CM, Perez RM, Narciso JL, Ferreira AP, Lemos LB, Medina-Pestana JO, et al. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance. Eur J Gastroenterol Hepatol. 2007;19:119–123
  62. Al-Harbi ASB, Malik GH, Subaity Y, Mansy H, Abutaleb N. Treatment of acute hepatitis C virus infection with alpha interferon in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2005;16:293–297
  63. Griveas I, Germanidis G, Visvardis G, Morice Y, Perelson AS, Pawlotsky JM, et al. Acute hepatitis C in patients receiving hemodialysis. Ren Fail. 2007;29:731–736
  64. Gursoy M, Gur G, Arslan H, Ozdemir N, Boyacioglu S. Interferon therapy in haemodialysis patients with acute hepatitis C virus infection and factors that predict response to treatment. J Viral Hepat. 2001;8:70–77
  65. Engel M, Malta FM, Gomes MM, Mello IM, Pinho JR, Ono-Nita SK, et al. Acute hepatitis C virus infection assessment among chronic hemodialysis patients in the Southwest Parana State, Brazil. BMC Public Health. 2007;7:50
  66. Manns MP, Meyer S, Wedemeyer H. The German network of excellence for viral hepatitis (Hep-Net). Hepatology. 2003;38:543–544
  67. Broers B, Helbling B, Francois A, Schmid P, Chuard C, Hadengue A, et al. Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C. J Hepatol. 2005;42:323–328

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00434-0

doi: 10.1016/j.jhep.2008.07.005

Journal of Hepatology
Volume 49, Issue 4 , Pages 625-633 , October 2008

Article Tools

* Image Usage & Resolution